The Obesity Drugs Wars: A Tale of Two Giants and a Questionable Comparison The pharmaceutical industry's obsession with weight loss has reached new heights, with two giants, Novo Nordisk and Eli Lilly, locked in a battle over market share and advertising claims.
At the center of this spat is a lawsuit filed by Novo Nordisk against its rival, accusing Eli Lilly of misleading consumers about its obesity drug Zepbound relative to Novo's own treatment, Wegovy.
The suit centers on a comparison between Zepbound and Wegovy, with Novo claiming that Eli Lilly's advertising misleads consumers by relying on outdated data.